Company news

Harrow, Inc. news in 2022

Harrow, Inc.'s news releases, calls and decks from 2022, newest first.

View company

Melt Pharmaceuticals’ MELT-300 (Midazolam 3mg and Ketamine 50mg Sublingual Tablet) Achieves Primary Sedation Endpoint in Phase 2 Pivotal Efficacy and Safety Study

December 20, 2022

Harrow Secures Capital to Close Recently Announced Acquisition

December 15, 2022

Harrow Prices $25 Million Offering

December 13, 2022

Harrow Enters into Agreement to Acquire Exclusive U.S. Rights to ILEVRO®, NEVANAC®, VIGAMOX®, MAXIDEX®, and TRIESENCE®

December 13, 2022

Harrow Announces Proposed Offering of $100 Million of Senior Notes Due 2027 and “BB” Rating from Egan-Jones

December 13, 2022

Harrow and iOR Partners Expand National Product Supply Agreement

November 29, 2022

Harrow Announces Third Quarter 2022 Financial Results

November 13, 2022

Harrow Launches Atropine.com

November 9, 2022

Harrow to Announce Third Quarter 2022 Financial Results on November 14, 2022

October 27, 2022

Harrow Sells Non-Ophthalmic Compounding Business

October 4, 2022

ImprimisRx Launches Fortisite™ (Tobramycin 1.5% + Vancomycin 5%) Compounded Antibiotic Formulation

September 28, 2022

Harrow Announces U.S. FDA Approval of IHEEZO™ (Chloroprocaine Hydrochloride Ophthalmic Gel) 3% for Ocular Surface Anesthesia

September 26, 2022

Harrow Health to Participate in H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference

August 10, 2022

Harrow Health Announces Second Quarter 2022 Financial Results

August 8, 2022

Harrow Health to Announce Second Quarter 2022 Financial Results on August 9, 2022

July 26, 2022

Harrow Health Announces Launch of IOPIDINE® 1% and MAXITROL® in the United States

June 23, 2022

Harrow Health Announces First Quarter 2022 Financial Results

May 4, 2022

Harrow Health to Participate in B. Riley Securities’ Annual Neuro & Ophthalmology Investor Conference

April 21, 2022

Harrow Health to Announce First Quarter 2022 Financial Results on May 5, 2022

April 19, 2022

Harrow Health Announces Appointments to Its Board of Directors

March 30, 2022

Harrow Health Announces Fourth Quarter and Year-End 2021 Financial Results

March 9, 2022

Harrow Health to Announce Fourth Quarter and Year-End 2021 Financial Results on March 10, 2022

February 23, 2022

Harrow Health Announces FDA Acceptance of New Drug Application for AMP-100

February 21, 2022

Harrow Health to Present at Aegis Virtual Conference

February 14, 2022

Harrow Health Publishes Corporate Transparency Report

February 7, 2022

Harrow Health to Participate in H.C. Wainwright BioConnect Conference

January 9, 2022

Melt Pharmaceuticals Submits INDs for MELT‑210 and MELT-400 to FDA

January 3, 2022

Calls in 2022

Decks in 2022